Table 1 Clinical indicators estimated, in the first year of follow-up, for prevalent patients with personality disorders treated by local DMHs, stratified for area (Lombardy, Emilia Romagna and Lazio Regions and Province of Palermo) and in the whole sample. QUADIM-MAP projects, Italy, 2015–2016
Lombardia (n = 16,196) | Emilia-Romagna (n = 9,462) | Palermo (n = 934) | Lazio (n = 5,096) | Whole sample (n = 31,688) | I2 ¥ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age-, gender-standardized treated prevalence rate (x 10,000) | 19.5 | 25.3 | 9.0 | 10.4 | 17.6 | ||||||||||
ACCESSIBILITY AND APPROPRIATENESS OF MENTAL HEALTH CARE | |||||||||||||||
1 | Patients with at least one outpatient contact in CMHCs or DCs | 92.3% | 98.4% | 74.2% | 97.4% | 94.4% | 99 | ||||||||
2 | Median number of outpatient contacts in CMHCs (per PY) | 8.0 | 13.0 | 7.0 | 10.0 | 9.5 | 99 | ||||||||
3 | Patients with at least one psychiatric visit | 81.7% | 83.9% | 65.1% | 76.5% | 81.0% | 99 | ||||||||
4 | Median number of outpatient psychiatric visits (per PY) | 4.0 | 4.0 | 3.0 | 5.0 | 4.0 | 99 | ||||||||
5 | Patients with at least one standardized assessment using tests | 4.3% | 2.6% | 2.2% | 5.0% | 3.8% | 97 | ||||||||
6 | Median number of standardized assessments using tests (per PY) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 0 | ||||||||
7 | Patients treated with at least one psychosocial intervention in CMHCs | 52.4% | 51.5% | 52.6% | 59.0% | 53.2% | 97 | ||||||||
8 | Median number of psychosocial interventions in CMHCs (per PY) | 6.0 | 4.0 | 3.0 | 5.0 | 4.5 | 98 | ||||||||
9 | Patients treated with at least one psychoeducation session ‡ | 3.1% | 4.9% | 6.2% | 3.8% | 97 | |||||||||
10 | Median number of psychoeducation sessions (per PY)‡ | 3.0 | 2.8 | 1.0 | 2.6 | 74 | |||||||||
11 | Patients treated with at least one psychotherapy session | 20.7% | 9.5% | 19.7% | 32.4% | 19.2% | 99 | ||||||||
12 | Median number of psychotherapy sessions (per PY) | 6.0 | 5.0 | 3.5 | 8.0 | 5.7 | 98 | ||||||||
13 | Median number of interventions specifically addressed to patients’ family members (per PY) | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 0 | ||||||||
14 | Patients treated with antipsychotic agents | 48.7% | 56.6% | 32.8% | 39.2% | 49.1% | 99 | ||||||||
15 | Patients treated with Mood Stabilizers | 44.1% | 50.2% | 37.8% | 40.5% | 45.1% | 98 | ||||||||
Patients treated with Lithium | 3.8% | 3.9% | 1.8% | 3.6% | 3.8% | 85 | |||||||||
Patients treated with Valproic acid, Carbamazepine | 16.8% | 18.0% | 26.3% | 22.8% | 18.4% | 97 | |||||||||
16 | Patients treated with Antidepressant agents | 46.1% | 55.4% | 32.0% | 31.7% | 46.1% | 99 | ||||||||
17 | Patients with at least one admission in residential facilities | 17.5% | 16.8% | 2.0% | 10.2% | 15.7% | 99 | ||||||||
18 | Median number of days spent in residential facilities (per PY) | 33.0 | 46.0 | 261.2 | 78.1 | 95.7 | 99 | ||||||||
19 | Patients with at least one admission in GHPW | 14.2% | 12.4% | 12.2% | 8.6% | 12.7% | 98 | ||||||||
20 | Median number of days spent in GHPW (per PY) | 14.0 | 13.5 | 18.0 | 15.0 | 14.0 | 0 | ||||||||
21 | Admissions with a length of stay in GHPW higher than 30 days | 5.8% | 2.3% | 5.5% | 4.7% | 5.0% | 92 | ||||||||
22 | Unplanned re-admissions in GHPW within 7 days¶ | 14.1% | 17.6% | 16.1% | 15.3% | 15.0% | 65 | ||||||||
23 | Unplanned re-admissions in GHPW within 30 days¶ | 27.3% | 31.6% | 35.5% | 27.8% | 28.5% | 77 | ||||||||
CONTINUITY OF MENTAL HEALTH CARE | |||||||||||||||
24 | Patients with continuous community care | 68.8% | 58.4% | 33.2% | 47.1% | 61.2% | 99 | ||||||||
25 | Patients persistent with Mood stabilizers therapy | 49.6% | 59.4% | 56.1% | 56.1% | 54.0% | 97 | ||||||||
26 | GHPW discharges followed by any mental health outpatient contact within 14 days | 54.4% | 77.0% | 51.6% | 67.0% | 60.4% | 99 | ||||||||
27 | GHPW discharges followed by an outpatient psychiatric visit within 14 days | 34.8% | 41.9% | 40.1% | 46.3% | 37.8% | 93 | ||||||||
28 | GHPW discharges followed by home care within 14 days § | 4.4% | 1.4% | 3.4% | 4.1% | 84 | |||||||||
SAFETY OF MENTAL HEALTH CARE | |||||||||||||||
29 | Patients monitored for hyperglycaemia and hyperlipidaemia (in patients treated with antipsychotics) | 26.4% | 26.4% | 25.5% | 20.3% | 25.6% | 92 | ||||||||
30 | Patients monitored with Lithaemia (in patients treated with Lithium) | 69.1% | 57.9% | 41.2% | 47.8% | 61.8% | 91 | ||||||||
31 | Patients with a complete set of clinical controls (in patients treated with Valproic acid, Carbamazepine) | 53.9% | 44.8% | 37.0% | 40.1% | 47.8% | 97 | ||||||||
32 | Patients with a complete set of clinical controls (in patients treated with Lamotrigine) | 46.4% | 38.8% | 30.8% | 37.0% | 41.5% | 56 | ||||||||
33 | Mortality (SMR), and relative 95% CI | 2.19 (1.96 to 2.45) | 2.08 (1.82 to 2.37) | 2.59 (1.69 to 3.84) | 1.46 (1.12 to 1.87) | 2.06 (1.90 to 2.23) | |||||||||